论文部分内容阅读
由于托卡朋(tolcapone,商品名Tasmar)引起严重肝脏毒性并导致3起死亡事件,日益引起人们关注,1998年11月12日欧洲药品评价局(EMEA)的药品专利委员会(CPMP)采纳了暂停托卡朋注册的意见。
The increasing concern that tolcapone (Tasmar) causes severe liver toxicity and 3 fatalities has led to the suspension of drug use by the Medicines Patent Board (CPMP) of the European Medicines Evaluation Service (EMEA) on November 12, 1998 Tokapan registration comments.